XLRN US00434H1086

Delayed Nasdaq - 11/19 04:00:00 pm
178.75	USD		-0.52%

11/22	ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index	CI
11/22	ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
11/22	ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officer..	AQ

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

11/15/2021	11/16/2021	11/17/2021	11/18/2021	11/19/2021	Date
173.5(c)	173.98(c)	179.68(c)	179.68(c)	178.75(c)	Last
496 861	850 750	6 009 272	1 025 355	7 884 284	Volume
+0.23%	+0.28%	+3.28%	0.00%	-0.52%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021
Net income 2021
Net Debt 2021
P/E ratio 2021
Yield 2021

Sales 2022	207 M - -
Net income 2022	-194 M - -
Net cash position 2022	14,7 M - -
P/E ratio 2022	-
Yield 2022	-

Capitalization	10 932 M 10 932 M -
EV / Sales 2021
EV / Sales 2022	52,9x
Nbr of Employees	312
Free-Float	88,0%

More Financials

Company

Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a...

Sector

Biotechnology & Medical Research

Calendar

03/02

Earnings Release

More about the company

Ratings of Acceleron Pharma Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about ACCELERON PHARMA INC.

11/22	ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index	CI
11/22	ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
11/22	ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delis..	AQ
11/22	Merck Completes Acceleron Pharma Acquisition	MT
11/22	Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.	AQ
11/22	Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share	MT
11/22	ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Composite Index	CI
11/22	ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Global BMI Index	CI
11/22	ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P TMI Index	CI
11/22	ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Biotechnology Select Industry Inde..	CI
11/19	Merck Completes Tender Offer to Acquire Acceleron Pharma Inc	CI
11/19	Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro..	CI
11/17	Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offe..	MT
11/17	Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer	BU
11/17	Merck Extends Tender Offer for Acceleron Pharma	MT

More news

News in other languages on ACCELERON PHARMA INC.

11/22	MERCK : l'acquisition d'Acceleron est finalisée
11/22	Merck conclut l'acquisition d'Acceleron Pharma
11/22	Merck conclut une offre publique d'achat en espèces visant à acquérir Acceleron Pharma ..
11/17	MERCK : l'OPA sur Acceleron va être prolongée
11/17	Merck prolonge son offre publique d'achat sur Acceleron Pharma

More news

Analyst Recommendations on ACCELERON PHARMA INC.

10/07	ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target	MT
10/04	ACCELERON PHARMA : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong..	MT
10/01	ACCELERON PHARMA : Oppenheimer Suspends Rating for Acceleron Pharma, $160 Price Target on ..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Merck to buy Acceleron for about $11.5 billion in rare disease drug push